Ofatumumab, a human anti‐CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease‐modifying antirheumatic drugs: Results of a randomized, double‐blind, placebo‐controlled, phase I/II study

Østergaard, Mikkel; Baslund, Bo; F. C. Rigby, William; Rojkovich, Bernadette; Jørgensen, Christian; T. Dawes, P.; Wiell, Charlotte; J. Wallace, Daniel; C. Tamer, Søren; Kastberg, Helle; Holm Petersen, Jørgen; Sierakowski, Stanisław

doi:10.1002/art.27524

Public

Ofatumumab, a human anti‐CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease‐modifying antirheumatic drugs: Results of a randomized, double‐blind, placebo‐controlled, phase I/II study

Published in Arthritis & Rheumatism • Apr 19, 2010

Authors:

Mikkel Østergaard

Bo Baslund

William F. C. Rigby

Abstract

OBJECTIVE: To investigate the safety and efficacy of ofatumumab, a novel human anti-CD20 monoclonal antibody (mAb), in patients with active rheumatoid arthritis (RA) whose disease did not respond to > or = 1 disease-modifying antirheumatic drug. METHODS: This combined phase I/II study investigated t...

Subject

Ofatumumab

Medicine

Rheumatoid arthritis

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!